2. Currently recruiting GCIG RCTs.

GOG 0252
Arm 1	Carboplatin AUC 6 IV for 6 cycles, given every 21 days + paclitaxel 80 mg/m2 IV on days 1, 8, and 15 + bevacizumab 15 mg/kg IV on day 1 in cycles 2‐6, then bevacizumab alone for cycles 7‐22
Arm 2	Carboplatin AUC 6 IP for 6 cycles, given every 21 days + paclitaxel 80 mg/m2 IV on days 1, 8, and 15 + bevacizumab 15 mg/kg IV on day 1 in cycles 2‐6, then bevacizumab alone for cycles 7‐22
Arm 3	Cisplatin 75 mg/m2  IP on day 2 for 6 cycles, given every 21 days + paclitaxel 135 mg/m2 IV on day 1 + paclitaxel 60 mg/m2 IP on day 8 + bevacizumab 15 mg/kg IV on day 1 in cycles 2‐6, then bevacizumab alone for cycles 7‐22
NCIC CTG OV21 3 ‐ 4 cycles of neoadjuvant platinum‐based chemotherapy after histologically confirmed initial diagnosis of advanced epithelial ovarian cancer, serous type peritoneal or fallopian tube cancer, followed by optimal cytoreduction (< 1 cm residual) then randomisation
Phase II portion of trial evaluating two IP regimes and one IV regime
Arm 1	Carboplatin AUC 5‐6 IV for 3 cycles, given every 21 days + paclitaxel 135 mg/m2 IV on day 1, and 60 mg/m2 on day 8
Arm 2	Cisplatin 75 mg/m2  IP for 3 cycles, given every 21 days + paclitaxel 135 mg/m2 IV on day 1, and 60 mg/m2 on day 8
Arm 3	Carboplatin AUC 5‐6 IP for 3 cycles, given every 21 days + paclitaxel 135 mg/m2 IV on day 1, and 60 mg/m2 on day 8
Phase III portion of trial comparing Arm 1 to either Arm 2 or Arm 3
GOTIC‐001/JGOG 3019
Arm 1	Carboplatin AUC 6 IV for 6‐8 cycles, given every 21 days + paclitaxel 80 mg/m2 IV on days 1, 8, and 15
Arm 2	Carboplatin AUC 6 IP for 6‐8 cycles, given every 21 days + paclitaxel 80 mg/m2 IV on days 1, 8, and 15